<\/p>\n
On Nov. 9, New York-based\u00a0Pfizer\u00a0and the German company\u00a0BioNTech\u00a0made history by presenting preliminary data indicating that their coronavirus vaccine was\u00a0over 90 percent effective<\/a><\/span>. It was the first time anyone had found such evidence. Just over a month later, on Dec. 11, the Food and Drug Administration granted it the first\u00a0emergency use authorization<\/a><\/span>\u00a0ever given by the United States to a coronavirus vaccine.<\/span><\/p>\n Dec. 18\u00a0 The F.D.A. authorizes\u00a0Moderna<\/strong><\/a>\u2019s vaccine for emergency use.<\/p>\n Dec. 18\u00a0 Cuba\u2019s\u00a0Soberana 2<\/strong><\/a>\u00a0vaccine moves to Phase 2.<\/p>\n Dec. 17\u00a0 Japan\u2019s\u00a0Shionogi<\/strong><\/a>\u00a0launches a Phase 1\/2 trial.<\/p>\n Dec. 17\u00a0 South Korea\u2019s\u00a0GeneOne<\/strong><\/a>\u00a0enters Phase 1\/2.<\/p>\n Dec. 17\u00a0 Clover Biopharmaceuticals<\/strong><\/a>\u00a0moves to Phase 2\/3.<\/p>\n Dec. 16\u00a0 Russia\u2019s\u00a0Vector Institute<\/strong><\/a>\u00a0moves to Phase 3.<\/p>\n Dec. 16\u00a0 French vaccine maker\u00a0Valneva<\/strong><\/a>\u00a0enters Phase 1\/2.<\/p>\n Dec. 16\u00a0 Vietnam\u2019s\u00a0Nanogen<\/strong><\/a>\u00a0enters Phase 1.<\/p>\n Dec. 14\u00a0 Russia announces efficacy data for\u00a0Gamaleya<\/strong><\/a>\u2019s Sputnik V vaccine.<\/p>\n Dec. 14\u00a0 CureVac<\/strong><\/a>\u00a0moves to Phase 3.<\/p>\n Dec. 14\u00a0 South Korea\u2019s\u00a0Cellid<\/strong><\/a>\u00a0and\u00a0LG Chem<\/strong><\/a>\u00a0enter Phase 1<\/p>\n
\nNew additions and recent updates<\/strong><\/span><\/h3>\n